Axim Biotechnologies, Inc.

Common Stock SEC Reporting - Current

OTC Disclosure & News Service


Photo Release -- AXIM Biotech CEO Addresses Cannabinoid Delivery Innovations at My Compassion's Cannabis Conference Chicago

Jun 23, 2015

OTC Disclosure & News Service


CHICAGO, June 23, 2015 (GLOBE NEWSWIRE) -- AXIM Biotechnologies, Inc. (OTC:AXIM), a unique hemp cannabis biotechnology innovator, is proud to announce that its Chief Executive Officer, George E. Anastassov, MD, DDS, MBA, is a featured guest speaker at the 2nd Annual Cannabis Conference Chicago. The Midwest's largest cannabis healthcare education conference takes place July 23-25 at Chicago's Navy Pier. There, Dr. Anastassov will present "Cannabinoid Delivery Innovations: What is on the Horizon for Retail and Pharmaceutical Products?" Natural components of the cannabis (hemp) plant are known as cannabinoids (e.g. CBD, CBG, THC, etc.).

George Anastassov
Dr. George E. Anastassov, MD, DDS, MBA and CEO of AXIM Biotech

A photo accompanying this release is available at

AXIM Biotech's core belief and mission is developing cannabinoid-based solutions to address current conditions with no known effective treatment including: Parkinson's disease, Alzheimer's disease / dementia, ADHD (attention deficit hyperactivity disorder), PTSD, autism, MS, spasticity, pain, RLS (restless leg syndrome), glaucoma, IBD, IBS and Crohn's disease.

According to the Census Bureau as of 2014, there are more than 12.8 million residents in the state of Illinois. Under the Illinois Compassionate Use of Medical Cannabis Act, patients must have been diagnosed with a debilitating condition by a physician; many of the debilitating conditions described in the Illinois Compassionate Use of Medical Cannabis Act fall under AXIM Biotech's mission.

Heidi Parikh, co-founder of My Compassion states, "My Compassion continues to make tremendous advancements in educating the public about the responsible use of medical cannabis. Our extensive educational and community outreach programs have earned us a prominent position and voice among patients, caregivers and healthcare professionals around the country. As the Illinois Compassionate Use of Medical Cannabis Act prepares to launch, Cannabis Conference Chicago provides key insight from prominent doctors and specialists with cannabis compassionate care experience."

Parikh continues, "We are grateful to Dr. Anastassov for contributing his time and expertise to educate patients, healthcare professionals and the public on advances in cannabinoid delivery methods. His company's research and development initiatives are in direct alignment with those who are attending the Cannabis Conference Chicago. This is critical information for those seeking treatment methods for conditions with no known cure."

Cannabis Conference Chicago's 2015 Medical Cannabis in Healthcare Symposium presenters are renowned medical doctors: George E. Anastassov, David Bearman, Robert Melamede, "Doc Rob" Streisfeld, and Dustin Sulak. Symposium presentation topics are:

  • Endocannabinoids and Medical Cannabis
  • Pharmacology and Effects of Cannabis
  • Cannabinoid Research and Therapeutics
  • Delivery and Dosage of Medical Cannabis
  • Illinois Medical Cannabis Laws and Physician Forms

Dr. Anastassov's professional background can be accessed here.

AXIM Biotech has been featured by media outlets including: FOX Business,, MJ Freeway, Chemical & Engineering News, Dental Tribune, Pharmaceutical Commerce, Dental Products Report and MJI News. For more information, visit AXIM Biotech's website.

To arrange for media interviews, contact Andrew Hard, Public Relations Spokesperson, at or call 858-380-5478.

About AXIM:

AXIM Biotechnologies, Inc. (OTC:AXIM) is an innovative biotechnology Company focusing on research, development and production of pharmaceutical, nutraceutical and cosmetic products where we prioritize the well-being of our customers while embracing a solid fiscal strategy. For more information, visit the Company website at


This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Axim Biotechnologies, Inc. to be materially different from the statements made herein.


AXIM Biotechnologies does not sell or distribute any products that are in violation of the United States Controlled Substances Act (US.CSA). The Company does grow, sell, and distribute hemp-based products.

The photo is also available at Newscom,, and via AP PhotoExpress. 

CONTACT: North American Address:
         18 East 50th Street, 5 Floor
         New York, NY 10022
         +1 844 294 6246
         European Address:
         Boelewerf 32, Unit 3
         2987 VD Ridderkerk, The Netherlands
         +31 10 8209 227


Copyright © 2015 GlobeNewswire. All Rights Reserved

The above news release has been provided by the above company via the OTC Disclosure and News Service. Issuers of news releases and not OTC Markets Group Inc. are solely responsible for the accuracy of such news releases.